BeOne Medicines Stock
BeOne Medicines AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- John V. Oyler
- Employees
- 12,000
- Market cap
- $39.4 B
- IPO
- 03/02/2016
BeOne Medicines AG is a healthcare company operating in the biotechnology sector, headquartered in Basel, Switzerland. Founded in 2010, the company focuses on discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
BeOne Medicines stock: price history
1D
-1.3%
1W
+4.1%
1M
+6.0%
6M
+14.0%
YTD
+21.5%
1Y
+16.0%
2Y
+66.1%
5Y
+3.0%
10Y
+1,070.9%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~2% stronger price swings than usual
BeOne Medicines stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
BeOne Medicines AG is a biotechnology company focused on oncology, headquartered in Basel, Switzerland. The business model concentrates on the discovery and development of innovative cancer therapies. The company has a broad portfolio of products in the commercialization phase, including medicines for treating various blood cancers and solid tumors such as BRUKINSA and TEVIMBRA. A substantial portion of revenue is generated through the sale of these products (99.1%), with the USA representing the most important market at 55.7%. Additionally, the company operates extensive research and development programs in clinical stages for various new active substances such as Bcl-2 or EGFR inhibitors. The company maintains strategic collaborations with renowned partners.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about BeOne Medicines
Analyst assessment of BeOne Medicines
PRICE TARGET LOW
US$367.00
CONSENSUS
US$406.22
MEDIAN
US$415.00
PRICE TARGET HIGH
US$459.00
0
STRONG BUY
14
BUY
0
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 08/10/2026
BeOne Medicines stock metrics
P/E
25.57
P/B
10.73
EV/EBITDA
32.2
RETURN ON EQUITY
4.6%
NET MARGIN
13.9%
DEBT/EQUITY
0.22
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
62.9%
FLOAT SHARES
67,181,319
AVG. DAILY VOLUME (30D)
399,643
Insider transactions (SEC)
Wang Xiaodong
Wang Xiaodong
Wang Xiaodong
Wang Xiaodong
Wang Xiaodong
Institutional holders
Comparable stocks
Frequently asked questions about BeOne Medicines stock
What does BeOne Medicines do?
BeOne Medicines AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is John V. Oyler, the company employs around 12,000 people.
The IPO was on 03/02/2016; the stock trades on NASDAQ under the ticker ONC.
What do analysts say about BeOne Medicines stock?
14 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$406.22, ranging from US$367.00 to US$459.00, with a median of US$415.00.
This is an external assessment, not a statement by Market Jury.
When does BeOne Medicines report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does BeOne Medicines pay a dividend?
No, BeOne Medicines currently does not pay a dividend.
Which stocks are comparable to BeOne Medicines?
Comparable stocks include Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx and Revolution Medicines.
How can I get BeOne Medicines stock analyzed?
Clicking "Analyze stock" lets five strategies assess BeOne Medicines against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.